MET H1094L

CI-VAR-00001877Explore in graph →NM_000245.4:c.3281A>TCIViC 2957

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
MET H1094L	Tepotinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7958 Mouse xenograft models using NIH3T3 cells stably expressing MET H1112L were established to test the efficiency of the MET inhibitor EMD1214063 (Tepotinib). The MET H1112L xenograft tumours showed comp… (full text at CIViC) PMID 24061647 · Medová et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.